Guselkumab regulatory update

Johnson & Johnson’s Janssen Research & Development LLC unit submitted a BLA to FDA for guselkumab to treat moderate to severe plaque psoriasis. The submission includes data from the Phase III VOYAGE 1 trial (see BioCentury, Oct. 10). MorphoSys said it received an undisclosed milestone payment triggered by the BLA submission...